天新藥業(603235.SH):股東自願延長股份鎖定期
格隆匯6月27日丨天新藥業(603235.SH)公佈,基於對公司未來持續穩定發展的信心以及對公司價值的認可,公司股東厚鼎投資、厚盛投資、厚泰投資承諾自願將其所持有的公司首次公開發行前的股份鎖定期,自2025年7月11日鎖定期滿之日起,延長6個月,至2026年1月11日。承諾在上述延長的鎖定期內,不轉讓或委託他人管理所持有的限售股股份,亦不會要求公司回購該部分股份。若因公司送紅股、轉增股本、配股等原因而導致所持股份數量增加,增加的股份同樣遵守上述延長鎖定期的承諾。待承諾的鎖定期屆滿後,所持股份的轉讓和交易將嚴格依照屆時有效的法律、法規,以及中國證券監督管理委員會、上海證券交易所的有關規定辦理。承諾嚴格履行上述約定,若違反本承諾,願意承擔由此產生的相應法律責任。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.